The Interleukin (IL)-1R1 pathway is a critical negative regulator of PyMT-mediated mammary tumorigenesis and pulmonary metastasis

OncoImmunology

Volumn 6, Issue 3, 2017, Pages

  Dagenais, Maryse ^a   Dupaul Chicoine, Jeremy ^a   Douglas, Todd ^a   Champagne, Claudia ^a   Morizot, Alexandre ^a   Saleh, Maya ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Breast cancer; IL 1R1; IL 1 ; inflammasome; inflammation; proliferation; tumor suppression

Indexed keywords

CYCLIN D1; CYTOKERATIN 14; CYTOKERATIN 8; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE 14; PHALLOIDIN; POLYOMA MIDDLE T ANTIGEN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VIRUS T ANTIGEN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ACTIVATED CELL SORTING; GENETIC ANALYSIS; GENOTYPE; GRANULOCYTE; IMMUNOFLUORESCENCE TEST; LUNG METASTASIS; MONOCYTE; MOUSE; MOUSE MAMMARY TUMOR VIRUS; NATURAL KILLER CELL; NONHUMAN; PALPATION; POLYOMAVIRUS; REAL TIME POLYMERASE CHAIN REACTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; TUNEL ASSAY; WESTERN BLOTTING; WOUND HEALING;

EID: 85016618997     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2017.1287247     Document Type: Article

References (67)

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide:sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136:E359-86; PMID:25220842; http://dx.doi.org/10.1002/ijc.29210
2. Hon JD, Singh B, Sahin A, Du G, Wang J, Wang VY, Deng FM, Zhang DY, Monaco ME, Lee P. Breast cancer molecular subtypes:from TNBC to QNBC. Am J Cancer Res 2016; 6:1864-72; PMID:27725895
3. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ, Panel members. Strategies for subtypes-dealing with the diversity of breast cancer:highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22:1736-47; PMID:21709140; http://dx.doi.org/10.1093/annonc/mdr304
4. Hanahan D, Weinberg RA. Hallmarks of cancer:the next generation. Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j.cell.2011.02.013
5. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60:277-300; PMID:20610543; http://dx.doi.org/10.3322/caac.20073
6. Hoos A. Development of immuno-oncology drugs–from CTLA4 to PD1 to the next generations. Nat Rev Drug Discov 2016; 15:235-47; PMID:26965203; http://dx.doi.org/10.1038/nrd.2015.35
7. Apte RN, Dotan S, Elkabets M, White MR, Reich E, Carmi Y, Song X, Dvozkin T, Krelin Y, Voronov E. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev 2006; 25:387-408; PMID:17043764; http://dx.doi.org/10.1007/s10555-006-9004-4
8. Dinarello CA. Why not treat human cancer with interleukin-1 blockade? Cancer Metastasis Rev 2010; 29:317-29; PMID:20422276; http://dx.doi.org/10.1007/s10555-010-9229-0
9. Dinarello CA. An expanding role for interleukin-1 blockade from gout to cancer. Mol Med 2014; 20 Suppl 1:S43-58; PMID:25549233; http://dx.doi.org/10.2119/molmed.2014.00232
10. Zitvogel L, Kepp O, Galluzzi L, Kroemer G. Inflammasomes in carcinogenesis and anticancer immune responses. Nat Immunol 2012; 13:343-51; PMID:22430787; http://dx.doi.org/10.1038/ni.2224
11. Di Paolo NC, Shayakhmetov DM. Interleukin 1alpha and the inflammatory process. Nat Immunol 2016; 17:906-13; PMID:27434011; http://dx.doi.org/10.1038/ni.3503
12. Auron PE, Webb AC, Rosenwasser LJ, Mucci SF, Rich A, Wolff SM, Dinarello CA. Nucleotide sequence of human monocyte interleukin 1 precursor cDNA. Proc Natl Acad Sci USA 1984; 81:7907-11; PMID:6083565; http://dx.doi.org/10.1073/pnas.81.24.7907
13. Lomedico PT, Gubler U, Hellmann CP, Dukovich M, Giri JG, Pan YC, Collier K, Semionow R, Chua AO, Mizel SB. Cloning and expression of murine interleukin-1 cDNA in Escherichia coli. Nature 1984; 312:458-62; PMID:6209582; http://dx.doi.org/10.1038/312458a0
14. March CJ, Mosley B, Larsen A, Cerretti DP, Braedt G, Price V, Gillis S, Henney CS, Kronheim SR, Grabstein K, et al. Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs. Nature 1985; 315:641-7; PMID:2989698; http://dx.doi.org/10.1038/315641a0
15. Kim B, Lee Y, Kim E, Kwak A, Ryoo S, Bae SH, Azam T, Kim S, Dinarello CA. The Interleukin-1α precursor is biologically active and is likely a key alarmin in the IL-1 family of cytokines. Front Immunol 2013; 4:391; PMID:24312098; http://dx.doi.org/10.3389/fimmu.2013.00391
16. He Y, Hara H, Nunez G. Mechanism and regulation of NLRP3 inflammasome activation. Trends Biochem Sci 2016; 41(12):1012-21; PMID:27669650; http://dx.doi.org/10.1016/j.tibs.2016.09.002
17. Afonina IS, Tynan GA, Logue SE, Cullen SP, Bots M, Luthi AU, Reeves EP, McElvaney NG, Medema JP, Lavelle EC, et al. Granzyme B-dependent proteolysis acts as a switch to enhance the proinflammatory activity of IL-1alpha. Mol Cell 2011; 44:265-78; PMID:22017873; http://dx.doi.org/10.1016/j.molcel.2011.07.037
18. Kurt-Jones EA, Beller DI, Mizel SB, Unanue ER. Identification of a membrane-associated interleukin 1 in macrophages. Proc Natl Acad Sci USA 1985; 82:1204-8; PMID:3919388; http://dx.doi.org/10.1073/pnas.82.4.1204
19. Wessendorf JH, Garfinkel S, Zhan X, Brown S, Maciag T. Identification of a nuclear localization sequence within the structure of the human interleukin-1 alpha precursor. J Biol Chem 1993; 268:22100-4; PMID:8408068
20. Apte RN, Dvorkin T, Song X, Fima E, Krelin Y, Yulevitch A, Gurfinkel R, Werman A, White RM, Argov S, et al. Opposing effects of IL-1 alpha and IL-1 beta on malignancy patterns. Tumor cell-associated IL-1 alpha potentiates anti-tumor immune responses and tumor regression, whereas IL-1 beta potentiates invasiveness. Adv Exp Med Biol 2000; 479:277-88; PMID:10897428
21. Song X, Voronov E, Dvorkin T, Fima E, Cagnano E, Benharroch D, Shendler Y, Bjorkdahl O, Segal S, Dinarello CA, et al. Differential effects of IL-1 alpha and IL-1 beta on tumorigenicity patterns and invasiveness. J Immunol 2003; 171:6448-56; PMID:14662844; http://dx.doi.org/10.4049/jimmunol.171.12.6448
22. Voronov E, Shouval DS, Krelin Y, Cagnano E, Benharroch D, Iwakura Y, Dinarello CA, Apte RN. IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci USA 2003; 100:2645-50; PMID:12598651; http://dx.doi.org/10.1073/pnas.0437939100
23. Krelin Y, Voronov E, Dotan S, Elkabets M, Reich E, Fogel M, Huszar M, Iwakura Y, Segal S, Dinarello CA, et al. Interleukin-1beta-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors. Cancer Res 2007; 67:1062-71; PMID:17283139; http://dx.doi.org/10.1158/0008-5472.CAN-06-2956
24. Murphy JE, Morales RE, Scott J, Kupper TS. IL-1 alpha, innate immunity, and skin carcinogenesis:the effect of constitutive expression of IL-1 alpha in epidermis on chemical carcinogenesis. J Immunol 2003; 170:5697-703; PMID:12759452; http://dx.doi.org/10.4049/jimmunol.170.11.5697
25. Giavazzi R, Garofalo A, Bani MR, Abbate M, Ghezzi P, Boraschi D, Mantovani A, Dejana E. Interleukin 1-induced augmentation of experimental metastases from a human melanoma in nude mice. Cancer Res 1990; 50:4771-5; PMID:2196116
26. Lauri D, Bertomeu MC, Orr FW, Bastida E, Sauder D, Buchanan MR. Interleukin-1 increases tumor cell adhesion to endothelial cells through an RGD dependent mechanism:in vitro and in vivo studies. Clin Exp Metastasis 1990; 8:27-32; PMID:2293911; http://dx.doi.org/10.1007/BF00155590
27. Lewis AM, Varghese S, Xu H, Alexander HR. Interleukin-1 and cancer progression:the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment. J Transl Med 2006; 4:48; PMID:17096856; http://dx.doi.org/10.1186/1479-5876-4-48
28. Douvdevani A, Huleihel M, Zoller M, Segal S, Apte RN. Reduced tumorigenicity of fibrosarcomas which constitutively generate IL-1 alpha either spontaneously or following IL-1 alpha gene transfer. Int J Cancer 1992; 51:822-30; PMID:1612788; http://dx.doi.org/10.1002/ijc.2910510526
29. Apte RN, Douvdevani A, Zoller M, White RM, Dvorkin T, Shimoni N, Fima E, Hacham M, Huleihel M, Benharroch D, et al. Cytokine-induced tumor immunogenicity:endogenous interleukin-1 alpha expressed by fibrosarcoma cells confers reduced tumorigenicity. Immunol Lett 1993; 39:45-52; PMID:8144190; http://dx.doi.org/10.1016/0165-2478(93)90163-V
30. Voronov E, Weinstein Y, Benharroch D, Cagnano E, Ofir R, Dobkin M, White RM, Zoller M, Barak V, Segal S, et al. Antitumor and immunotherapeutic effects of activated invasive T lymphoma cells that display short-term interleukin 1alpha expression. Cancer Res 1999; 59:1029-35; PMID:10070959
31. Dvorkin T, Song X, Argov S, White RM, Zoller M, Segal S, Dinarello CA, Voronov E, Apte RN. Immune phenomena involved in the in vivo regression of fibrosarcoma cells expressing cell-associated IL-1alpha. J Leukoc Biol 2006; 80:96-106; PMID:16707560; http://dx.doi.org/10.1189/jlb.0905509
32. Danforth DN, Jr, Sgagias MK. Interleukin-1 alpha and interleukin-6 act additively to inhibit growth of MCF-7 breast cancer cells in vitro. Cancer Res 1993; 53:1538-45; PMID:8453620
33. Sgagias MK, Kasid A, Danforth DN, Jr. Interleukin-1 alpha and tumor necrosis factor-alpha (TNF alpha) inhibit growth and induce TNF messenger RNA in MCF-7 human breast cancer cells. Mol Endocrinol 1991; 5:1740-7; PMID:1779975; http://dx.doi.org/10.1210/mend-5-11-1740
34. Morinaga Y, Hayashi H, Takeuchi A, Onozaki K. Antiproliferative effect of interleukin 1 (IL-1) on tumor cells:G0-G1 arrest of a human melanoma cell line by IL-1. Biochem Biophys Res Commun 1990; 173:186-92; PMID:2256913; http://dx.doi.org/10.1016/S0006-291X(05)81039-3
35. Maund SL, Barclay WW, Hover LD, Axanova LS, Sui G, Hipp JD, Fleet JC, Thorburn A, Cramer SD. Interleukin-1alpha mediates the antiproliferative effects of 1,25-dihydroxyvitamin D3 in prostate progenitor/stem cells. Cancer Res 2011; 71:5276-86; PMID:21653679; http://dx.doi.org/10.1158/0008-5472.CAN-10-2160
36. Maund SL, Shi L, Cramer SD. A role for interleukin-1 alpha in the 1,25 dihydroxyvitamin D3 response in mammary epithelial cells. PLoS One 2013; 8:e81367; PMID:24244740; http://dx.doi.org/10.1371/journal.pone.0081367
37. Guy CT, Cardiff RD, Muller WJ. Induction of mammary tumors by expression of polyomavirus middle T oncogene:a transgenic mouse model for metastatic disease. Mol Cell Biol 1992; 12:954-61; PMID:1312220; http://dx.doi.org/10.1128/MCB.12.3.954
38. Marcotte R, Muller WJ. Signal transduction in transgenic mouse models of human breast cancer–implications for human breast cancer. J Mammary Gland Biol Neoplasia 2008; 13:323-35; PMID:18651209; http://dx.doi.org/10.1007/s10911-008-9087-3
39. Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, Rasmussen KE, Jones LP, Assefnia S, Chandrasekharan S, et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 2007; 8:R76; PMID:17493263; http://dx.doi.org/10.1186/gb-2007-8-5-r76
40. Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson, Å, Kampf C, Sjöstedt E, Asplund A, et al. Proteomics. Tissue-based map of the human proteome. Science 2015; 347:1260419; PMID:25613900; http://dx.doi.org/10.1126/science.1260419
41. Mikaelian I, Hovick M, Silva KA, Burzenski LM, Shultz LD, Ackert-Bicknell CL, Cox GA, Sundberg JP. Expression of terminal differentiation proteins defines stages of mouse mammary gland development. Vet Pathol 2006; 43:36-49; PMID:16407485; http://dx.doi.org/10.1354/vp.43-1-36
42. Verderame M, Alcorta D, Egnor M, Smith K, Pollack R. Cytoskeletal F-actin patterns quantitated with fluorescein isothiocyanate-phalloidin in normal and transformed cells. Proc Natl Acad Sci USA 1980; 77:6624-8; PMID:6256751; http://dx.doi.org/10.1073/pnas.77.11.6624
43. Francia G, Cruz-Munoz W, Man S, Xu P, Kerbel RS. Mouse models of advanced spontaneous metastasis for experimental therapeutics. Nat Rev Cancer 2011; 11:135-41; PMID:21258397; http://dx.doi.org/10.1038/nrc3001
44. DeNardo DG, Barreto JB, Andreu P, Vasquez L, Tawfik D, Kolhatkar N, Coussens LM. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 2009; 16:91-102; PMID:19647220; http://dx.doi.org/10.1016/j.ccr.2009.06.018
45. Lin EY, Nguyen AV, Russell RG, Pollard JW. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 2001; 193:727-40; PMID:11257139; http://dx.doi.org/10.1084/jem.193.6.727
46. Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, Kaiser EA, Snyder LA, Pollard JW. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011; 475:222-5; PMID:21654748; http://dx.doi.org/10.1038/nature10138
47. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 2011; 1:54-67; PMID:22039576; http://dx.doi.org/10.1158/2159-8274.CD-10-0028
48. Szasz AM, Lanczky A, Nagy A, Forster S, Hark K, Green JE, Boussioutas A, Busuttil R, Szabó A, Győrffy B. Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients. Oncotarget 2016; 7(31):49322-33; PMID:27384994; http://dx.doi.org/10.18632/oncotarget.10337
49. Rider P, Carmi Y, Guttman O, Braiman A, Cohen I, Voronov E, White MR, Dinarello CA, Apte RN. IL-1alpha and IL-1beta recruit different myeloid cells and promote different stages of sterile inflammation. J Immunol 2011; 187:4835-43; PMID:21930960; http://dx.doi.org/10.4049/jimmunol.1102048
50. Gross O, Yazdi AS, Thomas CJ, Masin M, Heinz LX, Guarda G, Quadroni M, Drexler SK, Tschopp J. Inflammasome activators induce interleukin-1alpha secretion via distinct pathways with differential requirement for the protease function of caspase-1. Immunity 2012; 36:388-400; PMID:22444631; http://dx.doi.org/10.1016/j.immuni.2012.01.018
51. Derksen PW, Liu X, Saridin F, van der Gulden H, Zevenhoven J, Evers B, van Beijnum JR, Griffioen AW, Vink J, Krimpenfort P, et al. Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell 2006; 10:437-49; PMID:17097565; http://dx.doi.org/10.1016/j.ccr.2006.09.013
52. Coffelt SB, Kersten K, Doornebal CW, Weiden J, Vrijland K, Hau CS, Verstegen NJ, Ciampricotti M, Hawinkels LJ, Jonkers J, et al. IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis. Nature 2015; 522:345-8; PMID:25822788; http://dx.doi.org/10.1038/nature14282
53. Barak V, Nisman B, Polliack A, Vannier E, Dinarello CA. Correlation of serum levels of interleukin-1 family members with disease activity and response to treatment in hairy cell leukemia. Eur Cytokine Netw 1998; 9:33-9; PMID:9613675
54. Fujiwaki R, Iida K, Nakayama K, Kanasaki H, Hata K, Katabuchi H, Okamura H, Miyazaki K. Clinical significance of interleukin-1 receptor antagonist in patients with cervical carcinoma. Gynecol Oncol 2003; 89:77-83; PMID:12694657; http://dx.doi.org/10.1016/S0090-8258(02)00154-3
55. Mustea A, Pirvulescu C, Konsgen D, Braicu EI, Yuan S, Sun P, Lichtenegger W, Sehouli J. Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer. Cytokine 2008; 42:77-84; PMID:18329282; http://dx.doi.org/10.1016/j.cyto.2008.01.011
56. Kaminska J, Kowalska MM, Nowacki MP, Chwalinski MG, Rysinska A, Fuksiewicz M. CRP, TNF-alpha, IL-1ra, IL-6, IL-8 and IL-10 in blood serum of colorectal cancer patients. Pathol Oncol Res 2000; 6:38-41; PMID:10749586; http://dx.doi.org/10.1007/BF03032656
57. Ebrahimi B, Tucker SL, Li D, Abbruzzese JL, Kurzrock R. Cytokines in pancreatic carcinoma:correlation with phenotypic characteristics and prognosis. Cancer 2004; 101:2727-36; PMID:15526319; http://dx.doi.org/10.1002/cncr.20672
58. Lv M, Xiaoping X, Cai H, Li D, Wang J, Fu X, Yu F, Sun M, Lv Z. Cytokines as prognostic tool in breast carcinoma. Front Biosci (Landmark Ed) 2011; 16:2515-26; PMID:21622192; http://dx.doi.org/10.2741/3869
59. Ricote M, Garcia-Tunon I, Bethencourt FR, Fraile B, Paniagua R, Royuela M. Interleukin-1 (IL-1alpha and IL-1beta) and its receptors (IL-1RI, IL-1RII, and IL-1Ra) in prostate carcinoma. Cancer 2004; 100:1388-96; PMID:15042672; http://dx.doi.org/10.1002/cncr.20142
60. Iwagaki H, Hizuta A, Tanaka N. Interleukin-1 receptor antagonists and other markers in colorectal cancer patients. Scand J Gastroenterol 1997; 32:577-81; PMID:9200291; http://dx.doi.org/10.3109/00365529709025103
61. Ito H, Miki C. Profile of circulating levels of interleukin-1 receptor antagonist and interleukin-6 in colorectal cancer patients. Scand J Gastroenterol 1999; 34:1139-43; PMID:10582766; http://dx.doi.org/10.1080/003655299750024959
62. Parekh DJ, Ankerst DP, Baillargeon J, Higgins B, Platz EA, Troyer D, Hernandez J, Leach RJ, Lokshin A, Thompson IM. Assessment of 54 biomarkers for biopsy-detectable prostate cancer. Cancer Epidemiol Biomark Prev 2007; 16:1966-72; PMID:17932343; http://dx.doi.org/10.1158/1055-9965.EPI-07-0302
63. Niedzwiecki S, Stepien T, Kuzdak K, Stepien H, Krupinski R, Seehofer D, Rayes N, Ulrich F. Serum levels of interleukin-1 receptor antagonist (IL-1ra) in thyroid cancer patients. Langenbecks Arch Surg 2008; 393:275-80; PMID:18064485; http://dx.doi.org/10.1007/s00423-007-0251-9
64. Gherardi RK, Belec L, Soubrier M, Malapert D, Zuber M, Viard JP, Intrator L, Degos JD, Authier FJ. Overproduction of proinflammatory cytokines imbalanced by their antagonists in POEMS syndrome. Blood 1996; 87:1458-65; PMID:8608236
65. Poch B, Lotspeich E, Ramadani M, Gansauge S, Beger HG, Gansauge F. Systemic immune dysfunction in pancreatic cancer patients. Langenbecks Arch Surg 2007; 392:353-8; PMID:17235586; http://dx.doi.org/10.1007/s00423-006-0140-7
66. Qian B, Deng Y, Im JH, Muschel RJ, Zou Y, Li J, Lang RA, Pollard JW. A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth. PLoS One 2009; 4:e6562; PMID:19668347; http://dx.doi.org/10.1371/journal.pone.0006562
67. Dagenais M, Dupaul-Chicoine J, Champagne C, Skeldon A, Morizot A, Saleh M. A critical role for cellular inhibitor of protein 2 (cIAP2) in colitis-associated colorectal cancer and intestinal homeostasis mediated by the inflammasome and survival pathways. Mucosal Immunol 2016; 9:146-58; PMID:26037070; http://dx.doi.org/10.1038/mi.2015.46